TABLE 1
FROM:
A pilot clinical study of 
9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
M Guzmán, M J Duarte, C Blázquez, J Ravina, M C Rosa, I Galve-Roperh, C Sánchez, G Velasco and L González-Feria
BACK TO ARTICLETable 1. Summary of patient characteristics, treatment and outcome
| THC treatment | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient | Age (sex) | KPS | Tumour location | Recurrent-tumour volume (cm3) | Total days | Number of cycles | Total dose (mg) | Time between first and second surgery (wk) | Time from second surgery to death (wk) |
| 1 | 47 (m) | 90 | L–O | 120 | 30 | 2 | 1.46 | 70 | 19 |
| 2 | 58 (m) | 80 | R–T | 69 | 26 | 4 | 1.29 | 63 | 18 |
| 3 | 35 (m) | 80 | L–T | 40 | 64 | 6 | 3.29 | 9 | 53 |
| 4 | 67 (m) | 70 | R–T | 76 | 11 | 1 | 0.81 | 23 | 24 |
| 5 | 51 (f) | 70 | R–P | 41 | 15 | 2 | 1.13 | 28 | 17 |
| 6 | 64 (f) | 90 | R–T | 58 | 10 | 1 | 0.80 | 8 | 9 |
| 7 | 69 (f) | 90 | L–T | 43 | 21 | 3 | 1.68 | 112 | 29 |
| 8 | 51 (f) | 90 | R–F | 52 | 10 | 1 | 1.60 | 24 | 49 |
| 9 | 55 (f) | 70 | L–T | 76 | 11 | 1 | 1.28 | 38 | 24 |
Abbreviations: f=female; F=frontal; KPS=Karnofsky performance score; L=left; m=male; O=occipital; P=parietal; R=right; T=temporal; wk=week.
